 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Drug:
|
Duloxetine
|
|
Clinical Trial ID:
|
NCT00224302
|
|
Mode of action:
|
5-HT and NE transporter inhibitor
|
|
Phase:
|
POC Completed
|
|
Company:
|
Mental Health, Mannheim, Germany
|
|
Note:
|
Positive effect as add-on in depressive episodes, negative
and general psychopathology with stable positive symptoms
effect. No effect when added to clozapine.
|
Mico' U, Bruno A, Pandolfo G, Maria Romeo V, Mallamace D,
D'Arrigo C, Spina E, Zoccali RA, Muscatello MR. Duloxetine
as adjunctive treatment to clozapine in patients with
schizophrenia: a randomized, placebo-controlled trial. Int
Clin Psychopharmacol . 2011 Nov ; 26(6):303-10. Abstract
Englisch S, Knopf U, Scharnholz B, Kuwilsky A, Deuschle M,
Zink M. Duloxetine for major depressive episodes in the
course of psychotic disorders: an observational clinical
trial. J Psychopharmacol . 2009 Nov 1 ; 23(8):875-82. Abstract
Zink M, Knopf U, Mase E, Kuwilsky A, Deuschle M. Duloxetine
treatment of major depressive episodes in the course of
psychotic disorders. Pharmacopsychiatry . 2006 May 1 ;
39(3):109-11. Abstract
|
|
|
|
|
Text Size 
See our most recent Schizophrenia Bulletin theme Webinar: